相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。CXCR4 promotes the growth and metastasis of esophageal squamous cell carcinoma as a critical downstream mediator of HIF-1 alpha
Xianxian Wu et al.
CANCER SCIENCE (2022)
Antioxidant, antibacterial and anticancer efficacy of Alternaria chlamydospora-mediated gold nanoparticles
Fuad Ameen et al.
APPLIED NANOSCIENCE (2022)
The regulatory role of autophagy-related miRNAs in lung cancer drug resistance
Mahshid Shahverdi et al.
BIOMEDICINE & PHARMACOTHERAPY (2022)
Cancer combination therapies by silencing of CTLA-4, PD-L1, and TIM3 in osteosarcoma
Amin Daei Sorkhabi et al.
IUBMB LIFE (2022)
Dysregulation of Survivin-Targeting microRNAs in Autoimmune Diseases: New Perspectives for Novel Therapies
Navid Shomali et al.
FRONTIERS IN IMMUNOLOGY (2022)
The Basis and Advances in Clinical Application of Cytomegalovirus-Specific Cytotoxic T Cell Immunotherapy for Glioblastoma Multiforme
Amin Daei Sorkhabi et al.
FRONTIERS IN ONCOLOGY (2022)
Evaluation of the urine mRNA-PCA3 expression level in prostate patients; comparison between benign prostatic hyperplasia and cancer
Amid Yazdani et al.
IMMUNOPATHOLOGIA PERSA (2022)
Survivin; a novel therapeutic target that correlates with survival of autoreactive T lymphocytes obtained from patients with ankylosing spondylitis
Navid Shomali et al.
GENE (2022)
Silencing of SiX-4 enhances the chemosensitivity of melanoma cells to Cisplatin
Aysan Fallah Vazirabad et al.
PATHOLOGY RESEARCH AND PRACTICE (2022)
A simulation study of an applied approach to enhance drug recovery through electromembrane extraction
Mohammad Khosravikia et al.
JOURNAL OF MOLECULAR LIQUIDS (2022)
Lung cancer risk and the inhibitors of angiotensin converting enzyme; an updated review on recent evidence
Maryam Khosravian et al.
IMMUNOPATHOLOGIA PERSA (2022)
Prognostic implication of PD-L1 expression and associated tumor infiltrating lymphocytes in metastatic breast cancer
Mohamed M. Darwish et al.
IMMUNOPATHOLOGIA PERSA (2022)
Single nucleotide polymorphisms associated with gastric cancer in Iranian patients
Arash Alghasi et al.
IMMUNOPATHOLOGIA PERSA (2021)
Small molecule DNA-PK inhibitors as potential cancer therapy: a patent review (2010-present)
Suwen Hu et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2021)
A novel small molecule CXCR4 antagonist potently mobilizes hematopoietic stem cells in mice and monkeys
Xiao Fang et al.
STEM CELL RESEARCH & THERAPY (2021)
Pan-cancer analysis and experiments with cell lines reveal that the slightly elevated expression of DLGAP5 is involved in clear cell renal cell carcinoma progression
Yun Feng et al.
LIFE SCIENCES (2021)
A phase 1b trial of the CXCR4 inhibitor mavorixafor and nivolumab in advanced renal cell carcinoma patients with no prior response to nivolumab monotherapy
Toni K. Choueiri et al.
INVESTIGATIONAL NEW DRUGS (2021)
Padina boryana mediated green synthesis of crystalline palladium nanoparticles as potential nanodrug against multidrug resistant bacteria and cancer cells
Hana Sonbol et al.
SCIENTIFIC REPORTS (2021)
MgFe-LDH Nanoparticles: A Promising Leukemia Inhibitory Factor Replacement for Self-Renewal and Pluripotency Maintenance in Cultured Mouse Embryonic Stem Cells
Xiaolie He et al.
ADVANCED SCIENCE (2021)
Anti-Tumor Effect of Celastrol on Hepatocellular Carcinoma by the circ_SLIT3/miR-223-3p/CXCR4 Axis
Hailong Si et al.
CANCER MANAGEMENT AND RESEARCH (2021)
In Vivo Targeting of CXCR4-New Horizons
Margret Schottelius et al.
CANCERS (2021)
The CXCL12/CXCR7 signalling axis promotes proliferation and metastasis in cervical cancer
Leilei Xu et al.
MEDICAL ONCOLOGY (2021)
A highly selective and potent CXCR4 antagonist for hepatocellular carcinoma treatment
Jen-Shin Song et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)
CXCR4 intracellular protein promotes drug resistance and tumorigenic potential by inversely regulating the expression of Death Receptor 5
Mushtaq A. Nengroo et al.
CELL DEATH & DISEASE (2021)
MiR-146a suppresses the expression of CXCR4 and alters survival, proliferation and migration rate in colorectal cancer cells
Reyhaneh Afshar-Khamseh et al.
TISSUE & CELL (2021)
Biparatopic Protein Nanoparticles for the Precision Therapy of CXCR4+ Cancers
Olivia Cano-Garrido et al.
CANCERS (2021)
MiR-139 Modulates Cancer Stem Cell Function of Human Breast Cancer through Targeting CXCR4
Chun-Wen Cheng et al.
CANCERS (2021)
At the bench: Pre-clinical evidence for multiple functions of CXCR4 in cancer
Gary D. Luker et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2021)
A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma
Irene M. Ghobrial et al.
CLINICAL CANCER RESEARCH (2020)
Small molecule and peptide-based CXCR4 modulators as therapeutic agents. A patent review for the period from 2010 to 2018
Yesim A. Tahirovic et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2020)
CXCL12/CXCR4 signal transduction in diseases and its molecular approaches in targeted-therapy
Ashraf Mousavi
IMMUNOLOGY LETTERS (2020)
Dual CXCR4 and E-Selectin Inhibitor, GMI-1359, Shows Anti-Bone Metastatic Effects and Synergizes with Docetaxel in Prostate Cancer Cell Intraosseous Growth
Claudio Festuccia et al.
CELLS (2020)
Potential Anticancer Effect of Celastrol on Hepatocellular Carcinoma by Suppressing CXCR4-related Signal and Impeding Tumor Growth in Vivo
Chan Kun-Ming et al.
ARCHIVES OF MEDICAL RESEARCH (2020)
Nanoparticle Drug Delivery System for Glioma and Its Efficacy Improvement Strategies: A Comprehensive Review
Jie Li et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2020)
The emerging molecular mechanism of m6A modulators in tumorigenesis and cancer progression
Shuiping Liu et al.
BIOMEDICINE & PHARMACOTHERAPY (2020)
The CXCL12/CXCR4 axis confers temozolomide resistance to human glioblastoma cells via up-regulation of FOXM1
Shengwen Wang et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2020)
The Signaling Duo CXCL12 and CXCR4: Chemokine Fuel for Breast Cancer Tumorigenesis
Karolina A. Zielinska et al.
CANCERS (2020)
Wogonin reverses the drug resistance of chronic myelogenous leukemia cells to imatinib through CXCL12-CXCR4/7 axis in bone marrow microenvironment
Hanbo Cao et al.
ANNALS OF TRANSLATIONAL MEDICINE (2020)
Y Dual inhibitors of histone deacetylases and other cancer-related targets: A pharmacological perspective
Yuan Gao et al.
BIOCHEMICAL PHARMACOLOGY (2020)
Relevance of the CXCR4/CXCR7-CXCL12 axis and its effect in pathophysiological conditions
Christine Huynh et al.
PHARMACOLOGICAL RESEARCH (2020)
CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response
Daniele Biasci et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Relation between Immune cell response and stemness genes expression in breast cancer; A new approach in NANOG gene and Let7-a expression in breast cancer cell lines
Zeynab Aliyari-Serej et al.
IMMUNOPATHOLOGIA PERSA (2020)
Efficient isolation and identification of primary endothelial cells from bovine aorta by collagenase P
Faezeh Seif et al.
IMMUNOPATHOLOGIA PERSA (2020)
GLOBAL STABILIZATION OF THE FULL ATTRACTION-REPULSION KELLER-SEGEL SYSTEM
Hai-Yang Jin et al.
DISCRETE AND CONTINUOUS DYNAMICAL SYSTEMS (2020)
Factors associated with delayed diagnosis of breast cancer; a study in North-West of Iran
Nasrin Fouladi et al.
IMMUNOPATHOLOGIA PERSA (2020)
CXCR7 is not obligatory for CXCL12-CXCR4-induced epithelial-mesenchymal transition in human ovarian cancer
Ning Zheng et al.
MOLECULAR CARCINOGENESIS (2019)
Blocking CXCR4 alleviates desmoplasia, increases T-lymphocyte infiltration, and improves immunotherapy in metastatic breast cancer
Ivy X. Chen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Involvement of CXCR4 in Normal and Abnormal Development
Nanako Kawaguchi et al.
CELLS (2019)
Olaptesed pegol (NOX-A12) with bendamustine and rituximab: a phase IIa study in patients with relapsed/refractory chronic lymphocytic leukemia
Michael Steurer et al.
HAEMATOLOGICA (2019)
A multicenter phase 1 study of plerixafor and rituximab in patients with chronic lymphocytic leukemia
Leslie A. Andritsos et al.
LEUKEMIA & LYMPHOMA (2019)
Targeting CXCL12/CXCR4 Axis in Tumor Immunotherapy
Weiqiang Zhou et al.
CURRENT MEDICINAL CHEMISTRY (2019)
Inhibition of E-Selectin (GMI-1271) or E-selectin together with CXCR4 (GMI-1359) re-sensitizes multiple myeloma to therapy
Barbara Muz et al.
BLOOD CANCER JOURNAL (2019)
The role of CXCR4 in multiple myeloma: Cells' journey from bone marrow to beyond
Tomalika Rahmat Ullah
JOURNAL OF BONE ONCOLOGY (2019)
Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma
Irene M. Ghobrial et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
613PPhase I/II study with CXCL12 inhibitor NOX-A12 and pembrolizumab in patients with microsatellite-stable, metastatic colorectal or pancreatic cancer
N Halama et al.
ANNALS OF ONCOLOGY (2019)
CXCL12/CXCR4 promotes proliferation, migration, and invasion of adamantinomatous craniopharyngiomas via PI3K/AKT signal pathway
Xiaohong Yin et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2019)
The CXCR4 antagonist plerixafor (AMD3100) promotes proliferation of Ewing sarcoma cell lines in vitro and activates receptor tyrosine kinase signaling
Philipp Berning et al.
CELL COMMUNICATION AND SIGNALING (2018)
Effect of CXCR4 on Apoptosis in Osteosarcoma Cells via the PI3K/Akt/NF-kappa beta Signaling Pathway
Chunming Jiang et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2018)
The good and bad faces of the CXCR4 chemokine receptor
Joaquin Teixido et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2018)
Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial
Sonia Pernas et al.
LANCET ONCOLOGY (2018)
Hesperidin suppresses the migration and invasion of non-small cell lung cancer cells by inhibiting the SDF-1/CXCR-4 pathway
Rongmu Xia et al.
LIFE SCIENCES (2018)
Zerumbone targets the CXCR4-RhoA and PI3K-mTOR signaling axis to reduce motility and proliferation of oral cancer cells
Nur Syafinaz Zainal et al.
PHYTOMEDICINE (2018)
CXCR4/CXCR7/CXCL12-Axis in Follicular Thyroid Carcinoma
Thomas Artur Werner et al.
JOURNAL OF CANCER (2018)
Celastrol Attenuates the Invasion and Migration and Augments the Anticancer Effects of Bortezomib in a Xenograft Mouse Model of Multiple Myeloma
Muthu K. Shanmugam et al.
FRONTIERS IN PHARMACOLOGY (2018)
The Natural Compound Myricetin Effectively Represses the Malignant Progression of Prostate Cancer by Inhibiting PIM1 and Disrupting the PIM1/CXCR4 Interaction
Chen Ye et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2018)
Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia
Prajwal Boddu et al.
FRONTIERS IN ONCOLOGY (2018)
Nanobody-Fc constructs targeting chemokine receptor CXCR4 potently inhibit signaling and CXCR4-mediated HIV-entry and induce antibody effector functions
Vladimir Bobkov et al.
BIOCHEMICAL PHARMACOLOGY (2018)
RSL3 Drives Ferroptosis Through GPX4 Inactivation and ROS Production in Colorectal Cancer
Xinbing Sui et al.
FRONTIERS IN PHARMACOLOGY (2018)
Epithelial and endothelial mesenchymal transition and their role in diabetic kidney disease
Farahnaz Dadras et al.
JOURNAL OF RENAL INJURY PREVENTION (2018)
Reduced expression of CXCR4, a novel renal cancer stem cell marker, is associated with high-grade renal cell carcinoma
Arezoo Rasti et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2017)
CXCR4 inhibitors could benefit to HER2 but not to triple-negative breast cancer patients
S. Lefort et al.
ONCOGENE (2017)
Hormophysa triquerta polyphenol, an elixir that deters CXCR4-and COX2-dependent dissemination destiny of treatment-resistant pancreatic cancer cells
Sheeja Aravindan et al.
ONCOTARGET (2017)
The brain-penetrating CXCR4 antagonist, PRX177561, increases the antitumor effects of bevacizumab and sunitinib in preclinical models of human glioblastoma
Giovanni Luca Gravina et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF06747143) in chronic lymphocytic leukemia
Manoj K. Kashyap et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
The CXCR4 inhibitor BL-8040 induces the apoptosis of AML blasts by downregulating ERK, BCL-2, MCL-1 and cyclin-D1 via altered miR-15a/16-1 expression
M. Abraham et al.
LEUKEMIA (2017)
Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib-dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study
H. Ludwig et al.
LEUKEMIA (2017)
A randomized phase II study of LY2510924 and carboplatin/etoposide versus carboplatin/etoposide in extensive-disease small cell lung cancer
Ravi Salgia et al.
LUNG CANCER (2017)
Quercetin-3-O-glucuronide promotes the proliferation and migration of neural stem cells
Samrat Baral et al.
NEUROBIOLOGY OF AGING (2017)
Methanolic extract of Boswellia serrata exhibits anti-cancer activities by targeting microsomal prostaglandin E synthase-1 in human colon cancer cells
Tayebeh Ranjbarnejad et al.
PROSTAGLANDINS & OTHER LIPID MEDIATORS (2017)
The novel CXCR4 antagonist, PRX177561, reduces tumor cell proliferation and accelerates cancer stem cell differentiation in glioblastoma preclinical models
Giovanni Luca Gravina et al.
TUMOR BIOLOGY (2017)
Epithelial-to-mesenchymal transition correlates with gefitinib resistance in NSCLC cells and the liver X receptor ligand GW3965 reverses gefitinib resistance through inhibition of vimentin
Yong Hu et al.
ONCOTARGETS AND THERAPY (2017)
In Vitro Pro-apoptotic and Anti-migratory Effects of Ficus deltoidea L. Plant Extracts on the Human Prostate Cancer Cell Lines PC3
Mohd M. M. Hanafi et al.
FRONTIERS IN PHARMACOLOGY (2017)
Multifaceted C-X-C Chemokine Receptor 4 (CXCR4) Inhibition Interferes with Anti-Vascular Endothelial Growth Factor Therapy-Induced Glioma Dissemination
Jean-Pierre Gagner et al.
AMERICAN JOURNAL OF PATHOLOGY (2017)
Urtica dioica extract suppresses miR-21 and metastasis-related genes in breast cancer
Behzad Mansoori et al.
BIOMEDICINE & PHARMACOTHERAPY (2017)
A novel CXCR4 antagonist IgG1 antibody (PF-06747143) for the treatment of hematologic malignancies
Shu-Hui Liu et al.
BLOOD ADVANCES (2017)
miR-381 inhibited breast cancer cells proliferation, epithelial-to-mesenchymal transition and metastasis by targeting CXCR4
Yubao Xue et al.
BIOMEDICINE & PHARMACOTHERAPY (2017)
Apigenin, a potent suppressor of dendritic cell maturation and migration, protects against collagen-induced arthritis
Xing Li et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2016)
Molecular basis for the antagonistic activity of an anti-CXCR4 antibody
Li Peng et al.
MABS (2016)
CXCR7 mediates TGFβ1-promoted EMT and tumor-initiating features in lung cancer
Y-C Wu et al.
ONCOGENE (2016)
Ulocuplumab (BMS-936564 / MDX1338): a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathway
Manoj K. Kashyap et al.
ONCOTARGET (2016)
mTORC2 mediates CXCL12-induced angiogenesis
Mary E. Ziegler et al.
ANGIOGENESIS (2016)
miR-204-5p regulates cell proliferation and metastasis through inhibiting CXCR4 expression in OSCC
Xinjuan Wang et al.
BIOMEDICINE & PHARMACOTHERAPY (2016)
Survivin: a unique target for tumor therapy
Himani Garg et al.
CANCER CELL INTERNATIONAL (2016)
Drug design strategies focusing on the CXCR4/CXCR7/CXCL12 pathway in leukemia and lymphoma
Federica Barbieri et al.
EXPERT OPINION ON DRUG DISCOVERY (2016)
CXCR4 signaling in health and disease
Tommaso Pozzobon et al.
IMMUNOLOGY LETTERS (2016)
Preparation and characterization of a new monoclonal antibody against CXCR4 using lentivirus vector
Xinyi Li et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2016)
A New Anti-CXCR4 Antibody That Blocks the CXCR4/SDF-1 Axis and Mobilizes Effector Cells
Matthieu Broussas et al.
MOLECULAR CANCER THERAPEUTICS (2016)
MicroRNA-126 inhibits colon cancer cell proliferation and invasion by targeting the chemokine (C-X-C motif) receptor 4 and Ras homolog gene family, member A, signaling pathway
Wei Yuan et al.
ONCOTARGET (2016)
A phase I study of chemo-radiotherapy with plerixafor for newly diagnosed glioblastoma (GB).
Reena Parada Thomas et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
CXCR4 Antagonist TG-0054 Mobilizes Mesenchymal Stem Cells, Attenuates Inflammation, and Preserves Cardiac Systolic Function in a Porcine Model of Myocardial Infarction
Wan-Tseng Hsu et al.
CELL TRANSPLANTATION (2015)
Molecular Pathways: Targeting the CXCR4-CXCL12 Axis-Untapped Potential in the Tumor Microenvironment
Stefania Scala
CLINICAL CANCER RESEARCH (2015)
Quercetin reverses experimental pulmonary arterial hypertension by modulating the TrkA pathway
Yuanzhou He et al.
EXPERIMENTAL CELL RESEARCH (2015)
CXCR4 Protein Epitope Mimetic Antagonist POL5551 Disrupts Metastasis and Enhances Chemotherapy Effect in Triple-Negative Breast Cancer
Jingyu Xiang et al.
MOLECULAR CANCER THERAPEUTICS (2015)
CXCR4 pharmacogical inhibition reduces bone and soft tissue metastatic burden by affecting tumor growth and tumorigenic potential in prostate cancer preclinical models
Giovanni Luca Gravina et al.
PROSTATE (2015)
POL5551, a novel and potent CXCR4 antagonist, enhances sensitivity to chemotherapy in pediatric ALL
Edward Allan R. Sison et al.
ONCOTARGET (2015)
CXCR4 over-expression and survival in cancer: A system review and meta-analysis
Hongli Zhao et al.
ONCOTARGET (2015)
Discovery and Characterization of an Endogenous CXCR4 Antagonist
Onofrio Zirafi et al.
CELL REPORTS (2015)
MiR-451 Suppresses Cell Proliferation and Metastasis in A549 Lung Cancer Cells
Pin Yin et al.
MOLECULAR BIOTECHNOLOGY (2015)
Intrinsic TGF-β2-triggered SDF-1-CXCR4 signaling axis is crucial for drug resistance and a slow-cycling state in bone marrow-disseminated tumor cells
Takuya Nakamura et al.
ONCOTARGET (2015)
A Phase II, Open-Label Pilot Study to Evaluate the Hematopoietic Stem Cell Mobilization of TG-0054 Combined with G-CSF in 12 Patients with Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Lymphoma - an Interim Analysis
Gayatri Setia et al.
BLOOD (2015)
Randomized phase II study of sunitinib+CXCR4 inhibitor LY2510924 versus sunitinib alone in first-line treatment of patients with metastatic renal cell carcinoma.
John D. Hainsworth et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
CXCL12/CXCR4 axis confers adriamycin resistance to human chronic myelogenous leukemia and oroxylin A improves the sensitivity of K562/ADM cells
Yu Wang et al.
BIOCHEMICAL PHARMACOLOGY (2014)
The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization
Julia Hoellenriegel et al.
BLOOD (2014)
被撤回的出版物: Inhibition of breast cancer metastasis with microRNA-302a by downregulation of CXCR4 expression (Retracted article. See vol. 196, pg. 665, 2022)
Zhongxing Liang et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
SDF-1/CXCR4 promotes epithelial-mesenchymal transition and progression of colorectal cancer by activation of the Wnt/β-catenin signaling pathway
Ting-hua Hu et al.
CANCER LETTERS (2014)
Luteolin, ellagic acid and punicic acid are natural products that inhibit prostate cancer metastasis
Lei Wang et al.
CARCINOGENESIS (2014)
The High-Affinity CXCR4 Antagonist BKT140 Is Safe and Induces a Robust Mobilization of Human CD34+ Cells in Patients with Multiple Myeloma
Amnon Peled et al.
CLINICAL CANCER RESEARCH (2014)
A Phase I Trial of LY2510924, a CXCR4 Peptide Antagonist, in Patients with Advanced Cancer
Matthew D. Galsky et al.
CLINICAL CANCER RESEARCH (2014)
Targeted delivery of doxorubicin to A549 lung cancer cells by CXCR4 antagonist conjugated PLGA nanoparticles
Chuda Chittasupho et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2014)
CXCR4: A virus's best friend?
Kathleen L. Arnolds et al.
INFECTION GENETICS AND EVOLUTION (2014)
Fibroblast heterogeneity in the cancer wound
Daniel Oehlund et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2014)
CXC chemokine ligand 12 (CXCL12) and its receptor CXCR4
Takashi Nagasawa
JOURNAL OF MOLECULAR MEDICINE-JMM (2014)
Combination of Imatinib with CXCR4 Antagonist BKT140 Overcomes the Protective Effect of Stroma and Targets CML In Vitro and In Vivo
Katia Beider et al.
MOLECULAR CANCER THERAPEUTICS (2014)
miR-139 targets CXCR4 and inhibits the proliferation and metastasis of laryngeal squamous carcinoma cells
Hua-Nan Luo et al.
MEDICAL ONCOLOGY (2014)
Silibinin, a novel chemokine receptor type 4 antagonist, inhibits chemokine ligand 12-induced migration in breast cancer cells
Yan Wang et al.
PHYTOMEDICINE (2014)
Minimalist Hybrid Ligand/Receptor-Based Pharmacophore Model for CXCR4 Applied to a Small-Library of Marine Natural Products Led to the Identification of Phidianidine A as a New CXCR4 Ligand Exhibiting Antagonist Activity
Rosa Maria Vitale et al.
ACS CHEMICAL BIOLOGY (2013)
Inhibition of CXCR4-CXCL12 chemotaxis in melanoma by AMD11070
G. O'Boyle et al.
BRITISH JOURNAL OF CANCER (2013)
MEDI3185, a potent anti-CXCR4 antibody, inhibits tumor cell migration, signaling and tumor growth in preclinical models.
Adeela Kamal et al.
CANCER RESEARCH (2013)
BMS-936564/MDX-1338: A Fully Human Anti-CXCR4 Antibody Induces Apoptosis In Vitro and Shows Antitumor Activity In Vivo in Hematologic Malignancies
Michelle R. Kuhne et al.
CLINICAL CANCER RESEARCH (2013)
Development and Preclinical Characterization of a Humanized Antibody Targeting CXCL12
Cuiling Zhong et al.
CLINICAL CANCER RESEARCH (2013)
Targeting the CD20 and CXCR4 Pathways in Non-Hodgkin Lymphoma with Rituximab and High-Affinity CXCR4 Antagonist BKT140
Katia Beider et al.
CLINICAL CANCER RESEARCH (2013)
The role of CXCR3 and CXCR4 in colorectal cancer metastasis
Teppei Murakami et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Inhibitory effect of glyceollins on vasculogenesis through suppression of endothelial progenitor cell function
Jin-Hwa Choi et al.
MOLECULAR NUTRITION & FOOD RESEARCH (2013)
The novel CXCR4 antagonist POL5551 mobilizes hematopoietic stem and progenitor cells with greater efficiency than Plerixafor
D. Karpova et al.
LEUKEMIA (2013)
Upregulation of CXCR4 is functionally crucial for maintenance of stemness in drug-resistant non-small cell lung cancer cells
M-J Jung et al.
ONCOGENE (2013)
Small Molecule Inhibitors of CXCR4
Bikash Debnath et al.
THERANOSTICS (2013)
A Cyclopropane-Derived Stable Analog Of Fd-895 Induces Apoptosis and Inhibition Of mRNA Splicing In Lymphoma and Chronic Lymphocytic Leukemia: A Novel Therapeutic Approach
Deepak Kumar et al.
BLOOD (2013)
The molecular pharmacology of AMD11070: An orally bioavailable CXCR4 HIV entry inhibitor
Renee M. Mosi et al.
BIOCHEMICAL PHARMACOLOGY (2012)
A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia
Geoffrey L. Uy et al.
BLOOD (2012)
CXCR4 activation maintains a stem cell population in tamoxifen-resistant breast cancer cells through AhR signalling
A. Dubrovska et al.
BRITISH JOURNAL OF CANCER (2012)
Xanthohumol, a Prenylated Chalcone Derived from Hops, Suppresses Cancer Cell Invasion through Inhibiting the Expression of CXCR4 Chemokine Receptor
Y. Wang et al.
CURRENT MOLECULAR MEDICINE (2012)
Wnt Signaling Regulates Intermediate Precursor Production in the Postnatal Dentate Gyrus by Regulating Cxcr4 Expression
Youngshik Choe et al.
DEVELOPMENTAL NEUROSCIENCE (2012)
Contribution of endothelial progenitor cells to neovascularization
Da-Wei Li et al.
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE (2012)
In vitro and in vivo therapeutic efficacy of CXCR4 antagonist BKT140 against human non-small cell lung cancer
Duha Fahham et al.
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY (2012)
CXCL12 (SDF1α)-CXCR4/CXCR7 Pathway Inhibition: An Emerging Sensitizer for Anticancer Therapies?
Dan G. Duda et al.
CLINICAL CANCER RESEARCH (2011)
CXCR4 antagonist 4F-benzoyl-TN14003 inhibits leukemia and multiple myeloma tumor growth
Katia Beider et al.
EXPERIMENTAL HEMATOLOGY (2011)
Potential of CXCR4 antagonists for the treatment of metastatic lung cancer
Jan A. Burger et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2011)
CXCR4 peptide antagonist inhibits primary breast tumor growth, metastasis and enhances the efficacy of anti-VEGF treatment or docetaxel in a transgenic mouse model
Saima Hassan et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Ginsenoside Rg3 inhibits CXCR4 expression and related migrations in a breast cancer cell line
Xiao-ping Chen et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2011)
CXCR7/CXCR4 Heterodimer Constitutively Recruits β-Arrestin to Enhance Cell Migration
Fabien M. Decaillot et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Plumbagin inhibits invasion and migration of breast and gastric cancer cells by downregulating the expression of chemokine receptor CXCR4
Kanjoormana Aryan Manu et al.
MOLECULAR CANCER (2011)
CXCR4 Promotes Oral Squamous Cell Carcinoma Migration and Invasion through Inducing Expression of MMP-9 and MMP-13 via the ERK Signaling Pathway
Tao Yu et al.
MOLECULAR CANCER RESEARCH (2011)
Molecular control of endothelial cell behaviour during blood vessel morphogenesis
Shane P. Herbert et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2011)
MicroRNA-146a and AMD3100, two ways to control CXCR4 expression in acute myeloid leukemias
I. Spinello et al.
BLOOD CANCER JOURNAL (2011)
HIV-1 Entry Cofactor: Functional cDNA Cloing of a Seven-Transmembrane, G protein-Coupled Receptor
Yu Feng et al.
JOURNAL OF IMMUNOLOGY (2011)
CXCL12-CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy
S. Singh et al.
BRITISH JOURNAL OF CANCER (2010)
CXCL12/CXCR4/CXCR7 chemokine axis and cancer progression
Xueqing Sun et al.
CANCER AND METASTASIS REVIEWS (2010)
CXCL12 (SDF-1)/CXCR4 Pathway in Cancer
Beverly A. Teicher et al.
CLINICAL CANCER RESEARCH (2010)
CXCL12-CXCR4 Axis in Angiogenesis, Metastasis and Stem Cell Mobilization
S. Liekens et al.
CURRENT PHARMACEUTICAL DESIGN (2010)
Site-specific Phosphorylation of CXCR4 Is Dynamically Regulated by Multiple Kinases and Results in Differential Modulation of CXCR4 Signaling
John M. Busillo et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Celastrol suppresses invasion of colon and pancreatic cancer cells through the downregulation of expression of CXCR4 chemokine receptor
Vivek R. Yadav et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2010)
A CXCR4 Antagonist CTCE-9908 Inhibits Primary Tumor Growth and Metastasis of Breast Cancer (vol 155, pg 231, 2009)
Eugene H. Huang et al.
JOURNAL OF SURGICAL RESEARCH (2010)
FDA Review Summary: Mozobil in Combination with Granulocyte Colony-Stimulating Factor to Mobilize Hematopoietic Stem Cells to the Peripheral Blood for Collection and Subsequent Autologous Transplantation
Michael Brave et al.
ONCOLOGY (2010)
Beyond Desensitization: Physiological Relevance of Arrestin-Dependent Signaling
Louis M. Luttrell et al.
PHARMACOLOGICAL REVIEWS (2010)
The Chemokine Receptor CXCR4 and the Metalloproteinase MT1-MMP Are Mutually Required during Melanoma Metastasis to Lungs
Ruben A. Bartolome et al.
AMERICAN JOURNAL OF PATHOLOGY (2009)
The AMD3100 story: The path to the discovery of a stem cell mobilizer (Mozobil)
Erik De Clercq
BIOCHEMICAL PHARMACOLOGY (2009)
Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML
Zhihong Zeng et al.
BLOOD (2009)
Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100
Bruno Nervi et al.
BLOOD (2009)
CXCR4 receptor positive spheroid forming cells are responsible for tumor invasion in vitro
Alexander Krohn et al.
CANCER LETTERS (2009)
Efficient inhibition of SDF-1α-mediated chemotaxis and HIV-1 infection by novel CXCR4 antagonists
Yuki Iwasaki et al.
CANCER SCIENCE (2009)
Stromal cell-derived factor-1α (SDF-1α/CXCL12)-enhanced angiogenesis of human basal cell carcinoma cells involves ERK1/2-NF-κB/interleukin-6 pathway
Chia-Yu Chu et al.
CARCINOGENESIS (2009)
Strong expression of chemokine receptor CXCR4 by renal cell carcinoma cells correlates with metastasis
Linhui Wang et al.
CLINICAL & EXPERIMENTAL METASTASIS (2009)
Proof of Activity with AMD11070, an Orally Bioavailable Inhibitor of CXCR4-Tropic HIV Type 1
Graeme Moyle et al.
CLINICAL INFECTIOUS DISEASES (2009)
Recent patents regarding the discovery of small molecule CXCR4 antagonists
Cara A. Mosley et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2009)
CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers
J. A. Burger et al.
LEUKEMIA (2009)
Effects of CXCR4 Antagonist CTCE-9908 on Prostate Tumor Growth
Stacy Porvasnik et al.
PROSTATE (2009)
Chemokine signaling in cancer: One hump or two?
Joshua B. Rubin
SEMINARS IN CANCER BIOLOGY (2009)
TG-0054, a Novel and Potent Stem Cell Mobilizer, Displays Excellent PK/PD and Safety Profile in Phase I Trial
David T. Chung et al.
BLOOD (2009)
A CXCR4 Antagonist CTCE-9908 Inhibits Primary Tumor Growth and Metastasis of Breast Cancer
Eugene H. Huang et al.
JOURNAL OF SURGICAL RESEARCH (2009)
Blockade of SDF-1/CXCR4 signalling inhibits pancreatic cancer progression in vitro via inactivation of canonical Wnt pathway
Z. Wang et al.
BRITISH JOURNAL OF CANCER (2008)
The role of CXC chemokines and their receptors in cancer
Jo Vandercappellen et al.
CANCER LETTERS (2008)
Zerumbone Down-regulates Chemokine Receptor CXCR4 Expression Leading to Inhibition of CXCL12-Induced Invasion of Breast and Pancreatic Tumor Cells
Bokyung Sung et al.
CANCER RESEARCH (2008)
Chemokine receptor CXCR4 expression and prognosis in patients with metastatic prostate cancer
Takuya Akashi et al.
CANCER SCIENCE (2008)
Translating an Antagonist of Chemokine Receptor CXCR4: From Bench to Bedside
Donald Wong et al.
CLINICAL CANCER RESEARCH (2008)
New insights on the role of CXCR4 in cancer metastasis
A. Zlotnik
JOURNAL OF PATHOLOGY (2008)
Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastases
Su Young Kim et al.
CLINICAL & EXPERIMENTAL METASTASIS (2008)
17 beta-estradiol promotes breast cancer cell proliferation-inducing stromal cell-derived factor-1-mediated epidermal growth factor receptor transactivation: reversal by gefitinib pretreatment
Alessandra Pattarozzi et al.
MOLECULAR PHARMACOLOGY (2008)
Blockade of invasion and metastasis of bireast cancer cells via targeting CXCR4 with an artificial microRNA
Zhongxing Liang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2007)
Discovery of small molecule CXCR4 antagonists
Weiqiang Zhan et al.
JOURNAL OF MEDICINAL CHEMISTRY (2007)
Enhanced unique pattern of hematopoietic cell mobilization induced by the CXCR4 antagonist 4F-Benzoyl-TNI4003
Michal Abraham et al.
STEM CELLS (2007)
CXCR4/CXCL12 axis promotes VEGF-mediated tumor angiogenesis through Akt signaling pathway
Zhongxing Liang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2007)
CXC chemokine receptor-4 antagonist blocks both growth of primary tumor and metastasis of head and neck cancer in xenograft mouse models
Younghyoun Yoon et al.
CANCER RESEARCH (2007)
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance
James A. McCubrey et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2007)
Multiple-dose escalation study of the safety, pharmacokinetics, and biologic activity of oral AMD070, a selective CXCR4 receptor inhibitor, in human subjects
Nimalie D. Stone et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
The SDF-1-CXCR4 signaling pathway: a molecular hub modulating neo-angiogenesis
Isabelle Petit et al.
TRENDS IN IMMUNOLOGY (2007)
G protein regulation of MAPK networks
Z. G. Goldsmith et al.
ONCOGENE (2007)
The CXCR4 chemokine receptor in acute and chronic leukaemia:: a marrow homing receptor and potential therapeutic target
Jan A. Burger et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Blocking CXCR4-mediated cyclic AMP suppression inhibits brain tumor growth in vivo
Lihua Yang et al.
CANCER RESEARCH (2007)
Regulation of CXCR4 signaling
John M. Busillo et al.
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES (2007)
Hypoxia-inducible factor 1 and VEGF upregulate CXCR4 in glioblastoma: implications for angiogenesis and glioma cell invasion
David Zagzag et al.
LABORATORY INVESTIGATION (2006)
Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias
Zhihong Zeng et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches
Tatsuki Sugiyama et al.
IMMUNITY (2006)
The pleiotropic effects of the SDF-1-CXCR4 axis in organogenesis, regeneration and tumorigenesis
M. Z. Ratajczak et al.
LEUKEMIA (2006)
Human melanoma metastases express functional CXCR4
S Scala et al.
CLINICAL CANCER RESEARCH (2006)
CXCR4 chemokine receptor mediates prostate tumor cell adhesion through α5 and β3 Integrins
Tobias Engl et al.
NEOPLASIA (2006)
The chemokine receptor CXCR4 as a therapeutic target for several diseases
Hirokazu Tamamura et al.
MINI-REVIEWS IN MEDICINAL CHEMISTRY (2006)
CXCL12/CXCR4 signaling activates Akt-1 and MMP-9 expression in prostate cancer cells: The role of bone microenvironment-associated CXCL12
SR Chinni et al.
PROSTATE (2006)
The elevated level of CXCR4 is correlated with nodal metastasis of human breast cancer
H Kang et al.
BREAST (2005)
Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells
M Burger et al.
BLOOD (2005)
AMD3465, a monomacrocyclic CXCR4 antagonist and potent HIV entry inhibitor
S Hatse et al.
BIOCHEMICAL PHARMACOLOGY (2005)
Inhibitory effects of anti-CXCR4 antibodies on human colon cancer cells
A Ottaiano et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2005)
Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma
S Scala et al.
CLINICAL CANCER RESEARCH (2005)
Inhibition of breast cancer metastasis by selective synthetic polypeptide against CXCR4
ZX Liang et al.
CANCER RESEARCH (2004)
Chemokine receptors and melanoma metastasis
T Murakami et al.
JOURNAL OF DERMATOLOGICAL SCIENCE (2004)
The significance of cancer cell expression of the chemokine receptor CXCR4
F Balkwill
SEMINARS IN CANCER BIOLOGY (2004)
CXCR4-mediated adhesion and MMP-9 secretion in head and neck squamous cell carcinoma
GJ Samara et al.
CANCER LETTERS (2004)
Effects of inhibitors of the chemokine receptor CXCR4 on acute lymphoblastic leukemia cells in vitro
J Juarez et al.
LEUKEMIA (2003)
NF-κB promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4
G Helbig et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
A duodenally absorbable CXC chemokine receptor 4 antagonist, KRH-1636, exhibits a potent and selective anti-HIV-1 activity
K Ichiyama et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
The E3 ubiquitin ligase AIP4 mediates ubiquitination and sorting of the G protein-coupled receptor CXCR4
A Marchese et al.
DEVELOPMENTAL CELL (2003)
β-arrestin2 is critically involved in CXCR4-mediated chemotaxis, and this is mediated by its enhancement of p38 MAPK activation
Y Sun et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Dissemination and growth of cancer cells in metastatic sites
AF Chambers et al.
NATURE REVIEWS CANCER (2002)
New functions for the matrix metalloproteinases in cancer progression
M Egeblad et al.
NATURE REVIEWS CANCER (2002)
Diverse transcriptional response of CD4+ T cells to stromal cell-derived factor (SDF)-1:: Cell survival promotion and priming effects of SDF-1 on CD4+T cells
Y Suzuki et al.
JOURNAL OF IMMUNOLOGY (2001)
Chemokines and the molecular basis of cancer metastasis.
PM Murphy
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Development of specific CXCR4 inhibitors possessing high selectivity indexes as well as complete stability in serum based on an anti-HIV peptide T140
H Tamamura et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2001)
Involvement of chemokine receptors in breast cancer metastasis
A Müller et al.
NATURE (2001)
SDF-1 activity on microvascular endothelial cells: Consequences on angiogenesis in in vitro and in vivo models
F Mirshahi et al.
THROMBOSIS RESEARCH (2000)
分享论文
